Early detection of colorectal cancer: from conventional methods to novel biomarkers

Journal of Cancer Research and Clinical Oncology

Volumn 142, Issue 2, 2016, Pages 341-351

  Vatandoost, Nasimeh ^a   Ghanbari, Jahanafrooz ^a   Mojaver, Mahboobeh ^a   Avan, Amir ^b   Ghayour Mobarhan, Majid ^b   Nedaeinia, Reza ^b   Salehi, Rasoul ^a  

^a ISFAHAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b MASHHAD UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Colorectal cancer; Fecal serum biomarkers; Genomic epigenetic biomarkers; microRNA

Indexed keywords

TUMOR MARKER;

BLOOD; CHEMISTRY; COLONOSCOPY; COLORECTAL NEOPLASMS; EARLY CANCER DIAGNOSIS; FECES; HUMAN; METABOLISM; PROCEDURES; SIGMOIDOSCOPY;

BIOMARKERS, TUMOR; COLONOSCOPY; COLORECTAL NEOPLASMS; EARLY DETECTION OF CANCER; FECES; HUMANS; SIGMOIDOSCOPY;

EID: 84955707209     PISSN: 01715216     EISSN: 14321335     Source Type: Journal    
DOI: 10.1007/s00432-015-1928-z     Document Type: Review

References (111)

1. Abdullah M, Rani AA, Simadibrata M, Fauzi A, Syam AF (2012) The value of fecal tumor M2 pyruvate kinase as a diagnostic tool for colorectal cancer screening. Acta med Indones 44:94–99
2. Ahangari F, Salehi R, Salehi M, Khanahmad H (2014) A miRNA-binding site single nucleotide polymorphism in the 3′-UTR region of the NOD2 gene is associated with colorectal cancer. Med Oncol 31:173. doi:10.1007/s12032-014-0173-7
3. Ahmed FE et al (2013) Diagnostic microRNA markers to screen for sporadic human colon cancer in stool: I Proof of principle. Cancer genomics & proteomics 10:93–113
4. Ali DAM (2010) Identification of novel epigenetic biomarkers in colorectal cancer GLDC and PPP1R14A., in Department of Molecular Biosciences (IMBV), Faculty of Mathematics and Natural sciences UNIVERSITY OF OSLO
5. Bartel DP (2004) MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 116:281–297
6. Bendardaf R, Lamlum H, Pyrhonen S (2004) Prognostic and predictive molecular markers in colorectal carcinoma. Anticancer Res 24:2519–2530
7. Berezikov E, Guryev V, van de Belt J, Wienholds E, Plasterk RH, Cuppen E (2005) Phylogenetic shadowing and computational identification of human microRNA genes. Cell 120:21–24. doi:10.1016/j.cell.2004.12.031
8. Berg M, Soreide K (2011) Genetic and epigenetic traits as biomarkers in colorectal cancer. Int J Mol Sci 12:9426–9439. doi:10.3390/ijms12129426
9. Bretthauer M (2011) Colorectal cancer screening. J Intern Med 270:87–98. doi:10.1111/j.1365-2796.2011.02399.x
10. Carmona FJ et al (2013) DNA methylation biomarkers for noninvasive diagnosis of colorectal cancer. Cancer Prev Res 6:656–665. doi:10.1158/1940-6207.CAPR-12-0501
11. Chan CC et al (2010) Multiple serological biomarkers for colorectal cancer detection. Int J Cancer 126:1683–1690. doi:10.1002/ijc.24912
12. Chang W et al (2011) Development of autoantibody signatures as biomarkers for early detection of colorectal carcinoma. Clin Cancer Res 17:5715–5724. doi:10.1158/1078-0432.CCR-11-0199
13. Chen C-C, Yang S-H, Lin J-K, Lin T-C, Chen W-S, Jiang J-K et al (2005a) Is it reasonable to add preoperative serum level of CEA and CA19-9 to staging for colorectal cancer? J Surg Res 124:169–174
14. Chen WD et al (2005b) Detection in fecal DNA of colon cancer-specific methylation of the nonexpressed vimentin gene. J Natl Cancer Inst 97:1124–1132. doi:10.1093/jnci/dji204
15. Chen K, Song F, Calin GA, Wei Q, Hao X, Zhang W (2008a) Polymorphisms in microRNA targets: a gold mine for molecular epidemiology. Carcinogenesis 29:1306–1311. doi:10.1093/carcin/bgn116
16. Chen X et al (2008b) Characterization of microRNAs in serum: a novel class of biomarkers for diagnosis of cancer and other diseases. Cell Res 18:997–1006. doi:10.1038/cr.2008.282
17. Chen H, Werner S, Tao S, Zornig I, Brenner H (2014) Blood autoantibodies against tumor-associated antigens as biomarkers in early detection of colorectal cancer. Cancer Lett 346:178–187. doi:10.1016/j.canlet.2014.01.007
18. Colorectal Cancer Facts and Figures (2013)
19. Coppede F, Lopomo A, Spisni R, Migliore L (2014) Genetic and epigenetic biomarkers for diagnosis, prognosis and treatment of colorectal cancer. World J Gastroenterol: WJG 20:943–956. doi:10.3748/wjg.v20.i4.943
20. Daraei A, Salehi R, Mohamadhashem F (2011) DNA-methyltransferase 3B 39179 G > T polymorphism and risk of sporadic colorectal cancer in a subset of Iranian population. J Res Med Sci: The Official Journal of Isfahan University of Medical Sciences 16:807–813
21. Daraei A, Salehi R, Mohamadhashem F (2012a) PTGS2 (COX2) -765G > C gene polymorphism and risk of sporadic colorectal cancer in Iranian population. Mol Biol Rep 39:5219–5224. doi:10.1007/s11033-011-1319-8
22. Daraei A, Salehi R, Salehi M, Emami MH, Janghorbani M, Mohamadhashem F, Tavakoli H (2012b) Effect of rs6983267 polymorphism in the 8q24 region and rs4444903 polymorphism in EGF gene on the risk of sporadic colorectal cancer in Iranian population. Med Oncol 29:1044–1049. doi:10.1007/s12032-011-9980-2
23. De Maio G, Rengucci C, Zoli W, Calistri D (2014) Circulating and stool nucleic acid analysis for colorectal cancer diagnosis. World Journal of Gastroenterol: WJG 20:957–967. doi:10.3748/wjg.v20.i4.957
24. Deschoolmeester V et al (2010) A review of the most promising biomarkers in colorectal cancer: one step closer to targeted therapy. Oncologist 15:699–731
25. Desmetz C, Mange A, Maudelonde T, Solassol J (2011) Autoantibody signatures: progress and perspectives for early cancer detection. J Cell Mol Med 15:2013–2024. doi:10.1111/j.1582-4934.2011.01355.x
26. deVos T et al (2009) Circulating methylated SEPT9 DNA in plasma is a biomarker for colorectal cancer. Clin Chem 55:1337–1346. doi:10.1373/clinchem.2008.115808
27. Dong SM et al (2001) Detecting colorectal cancer in stool with the use of multiple genetic targets. J Natl Cancer Inst 93:858–865
28. Duffy MJ (2001) Carcinoembryonic antigen as a marker for colorectal cancer: is it clinically useful? Clin Chem 47:624–630
29. Federico Sopeña M, M. Angel Ferrandez, and M. Angel Lanas (2008) Noninvasive Diagnostic Modalities for Early Detection of Colorectal Cancer. Curr Colorectal Cancer Report 4(1):24–33
30. Franz M, Scholz M, Henze I, Rockl S, Gomez LI (2013) Detection of colon polyps by a novel, polymer pattern-based full blood test. Journal of Translational Medicine 11:278. doi:10.1186/1479-5876-11-278
31. Fung KY et al (2014) Colorectal cancer biomarkers: to be or not to be? Cautionary tales from a road well travelled. World J Gastroenterol: WJG 20:888–898. doi:10.3748/wjg.v20.i4.888
32. GOEL A (2012) Reviews in basic and clinical gastroenterology and hepatology. Gastroenterol Rep 143:1442–1460
33. Hanke M et al (2010) A robust methodology to study urine microRNA as tumor marker: microRNA-126 and microRNA-182 are related to urinary bladder cancer. Urol Oncol 28:655–661. doi:10.1016/j.urolonc.2009.01.027
34. Hardt PD, Mazurek S, Toepler M, Schlierbach P, Bretzel RG, Eigenbrodt E, Kloer HU (2004) Faecal tumour M2 pyruvate kinase: a new, sensitive screening tool for colorectal cancer. Br J Cancer 91:980–984. doi:10.1038/sj.bjc.6602033
35. Huang Z, Huang D, Ni S, Peng Z, Sheng W, Du X (2010) Plasma microRNAs are promising novel biomarkers for early detection of colorectal cancer. Int J Cancer 127:118–126. doi:10.1002/ijc.25007
36. Huang CJ, Yang SH, Lee CL, Cheng YC, Tai SY, Chien CC (2013) Ribosomal protein S27-like in colorectal cancer: a candidate for predicting prognoses. PLoS one 8:e67043. doi:10.1371/journal.pone.0067043
37. Hunter MP et al (2008) Detection of microRNA expression in human peripheral blood microvesicles. PLoS one 3:e3694. doi:10.1371/journal.pone.0003694
38. Imperiale TF, Ransohoff DF, Itzkowitz SH, Turnbull BA, Ross ME, Colorectal Cancer Study G (2004) Fecal DNA versus fecal occult blood for colorectal-cancer screening in an average-risk population. N Engl J Med 351:2704–2714. doi:10.1056/NEJMoa033403
39. Itzkowitz S et al (2008) A simplified, noninvasive stool DNA test for colorectal cancer detection. Am J Gastroenterol 103:2862–2870. doi:10.1111/j.1572-0241.2008.02088.x
40. Kanaan Z, Rai SN, Eichenberger MR, Roberts H, Keskey B, Pan J, Galandiuk S (2012) Plasma miR-21: a potential diagnostic marker of colorectal cancer. Ann Surg 256:544–551. doi:10.1097/SLA.0b013e318265bd6f
41. Kanthan R, Senger JL, Kanthan SC (2012) Fecal molecular markers for colorectal cancer screening. Gastroenterol Res Pract 2012:184343. doi:10.1155/2012/184343
42. Kim HJ, Yu MH, Kim H, Byun J, Lee C (2008) Noninvasive molecular biomarkers for the detection of colorectal cancer. BMB Rep 41:685–692
43. Kjersem JB et al (2012) Let-7 miRNA-binding site polymorphism in the KRAS 3′UTR; colorectal cancer screening population prevalence and influence on clinical outcome in patients with metastatic colorectal cancer treated with 5-fluorouracil and oxaliplatin ± cetuximab. BMC Cancer 12:534. doi:10.1186/1471-2407-12-534
44. Kloosterman WP, Plasterk RH (2006) The diverse functions of microRNAs in animal development and disease. Dev Cell 11:441–450. doi:10.1016/j.devcel.2006.09.009
45. Kostova E et al (2014) Expression of matrix metalloproteinases 2, 7 and 9 in patients with colorectal cancer. Vojnosanit Pregl 71:52–59
46. Kumar Y, Tapuria N, Kirmani N, Davidson BR (2007) Tumour M2-pyruvate kinase: a gastrointestinal cancer marker. Eur J Gastroenterol Hepatol 19:265–276. doi:10.1097/MEG.0b013e3280102f78
47. Landi D, Gemignani F, Naccarati A, Pardini B, Vodicka P, Vodickova L, Novotny J, Försti A, Hemminki K, Canzian F, Landi S (2008) Polymorphisms within micro-RNA-binding sites and risk of sporadic colorectal cancer. Carcinogenesis 29:579–584
48. Landi D, Gemignani F, Pardini B et al (2012) Identification of candidate genes carrying polymorphisms associated with the risk of colorectal cancer by analyzing the colorectal mutome and microRNAome. Cancer Cell 118:4670–4680
49. Lee MA, Park JH, Rhyu SY, Oh ST, Kang WK, Kim HN (2014) Wnt3a expression is associated with MMP-9 expression in primary tumor and metastatic site in recurrent or stage IV colorectal cancer. BMC Cancer 14:125. doi:10.1186/1471-2407-14-125
50. Leung WK et al (2005) Quantitative detection of promoter hypermethylation in multiple genes in the serum of patients with colorectal cancer. Am J Gastroenterol 100:2274–2279. doi:10.1111/j.1572-0241.2005.50412.x
51. Levin B, Brooks D, Smith RA, Stone A (2003) Emerging technologies in screening for colorectal cancer: cT colonography, immunochemical fecal occult blood tests, and stool screening using molecular markers. CA Cancer J Clin 53:44–55
52. Lewis BP, Burge CB, Bartel DP (2005) Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets. Cell 120:15–20. doi:10.1016/j.cell.2004.12.035
53. Li JM et al (2012) Down-regulation of fecal miR-143 and miR-145 as potential markers for colorectal cancer. Saudi Med J 33:24–29
54. Link A et al (2010) Fecal MicroRNAs as novel biomarkers for colon cancer screening. Cancer Epidemiol Biomarkers Prev 19:1766–1774
55. Lofton-Day C et al (2008) DNA methylation biomarkers for blood-based colorectal cancer screening. Clin Chem 54:414–423. doi:10.1373/clinchem.2007.095992
56. Loitsch SM, Shastri Y, Stein J (2008) Stool test for colorectal cancer screening–it’s time to move! Clin Lab 54:473–484
57. Lovat F, Valeri N, Croce CM (2011) MicroRNAs in the pathogenesis of cancer. Semin Oncol 38:724–733. doi:10.1053/j.seminoncol.2011.08.006
58. Luo X, Stock C, Burwinkel B, Brenner H (2013) Identification and evaluation of plasma microRNAs for early detection of colorectal cancer. PloS one 8:e62880. doi:10.1371/journal.pone.0062880
59. Magnusson K et al (2011) SATB2 in combination with cytokeratin 20 identifies over 95 % of all colorectal carcinomas. Am J Surg Pathol 35:937–948. doi:10.1097/PAS.0b013e31821c3dae
60. Mathivanan S (2012) Quest for cancer biomarkers: assaying mutant proteins and RNA that provides the much needed specificity. J Proteomics Bioinformat 5
61. Mazeh H et al (2013) The diagnostic and prognostic role of microRNA in colorectal cancer—a comprehensive review. J Cancer 4:281–295. doi:10.7150/jca.5836
62. Mishra PJ, Bertino JR (2009) MicroRNA polymorphisms: the future of pharmacogenomics, molecular epidemiology and individualized medicine. Pharmacogenomics 10:399–416. doi:10.2217/14622416.10.3.399
63. Mishra PJ, Humeniuk R, Mishra PJ, Longo-Sorbello GS, Banerjee D, Bertino JR (2007) A miR-24 microRNA binding-site polymorphism in dihydrofolate reductase gene leads to methotrexate resistance. Proc Natl Acad Sci USA 104:13513–13518. doi:10.1073/pnas.0706217104
64. Mishra PJ, Mishra PJ, Banerjee D, Bertino JR (2008) MiRSNPs or MiR-polymorphisms, new players in microRNA mediated regulation of the cell: introducing microRNA pharmacogenomics. Cell Cycle 7:853–858
65. Moghimi-Dehkordi B, Safaee A (2012) An overview of colorectal cancer survival rates and prognosis in Asia. World J Gastrointest Oncol 4:71–75. doi:10.4251/wjgo.v4.i4.71
66. Mori Y et al (2011) Novel candidate colorectal cancer biomarkers identified by methylation microarray-based scanning. Endocr Relat Cancer 18:465–478. doi:10.1530/ERC-11-0083
67. Mulder SA, van Leerdam ME, van Vuuren AJ, Francke J, van Toorenenbergen AW, Kuipers EJ, Ouwendijk RJ (2007) Tumor pyruvate kinase isoenzyme type M2 and immunochemical fecal occult blood test: performance in screening for colorectal cancer. Eur J Gastroenterol Hepatol 19:878–882. doi:10.1097/MEG.0b013e3282cfa49c
68. Naccarati A et al (2012) Polymorphisms in miRNA-binding sites of nucleotide excision repair genes and colorectal cancer risk. Carcinogenesis 33:1346–1351. doi:10.1093/carcin/bgs172
69. Offenberg H, Brunner N, Mansilla F, Orntoft Torben F, Birkenkamp-Demtroder K (2008) TIMP-1 expression in human colorectal cancer is associated with TGF-B1, LOXL2, INHBA1, TNF-AIP6 and TIMP-2 transcript profiles. Mol Oncol 2:233–240. doi:10.1016/j.molonc.2008.06.003
70. Orabona C et al (2004) CD28 induces immunostimulatory signals in dendritic cells via CD80 and CD86. Nat Immunol 5:1134–1142. doi:10.1038/ni1124
71. Ouyang DL, Chen JJ, Getzenberg RH, Schoen RE (2005) Noninvasive testing for colorectal cancer: a review. Am J Gastroenterol 100:1393–1403. doi:10.1111/j.1572-0241.2005.41427.x
72. Pardini B, Rosa F, Barone E et al (2013) Variation within 3′-UTRs of base excision repair genes and response to therapy in colorectal cancer patients: a potential modulation of microRNAs binding. Clin Cancer Res 19:6044–6056
73. Passarge E (2007) Color Atlas of genetics. Thieme Verlag KG, New York, NY
74. Pitule P et al (2013) Assessing colorectal cancer heterogeneity: one step closer to tailored medicine. J Appl Biomed 11:115–129
75. Pox C (2011) Colon cancer screening: which non-invasive filter tests? Dig Dis 29(Suppl 1):56–59. doi:10.1159/000331127
76. Quintero E (2009) Chemical or immunological tests for the detection of fecal occult blood in colorectal cancer screening? Gastroenterol Hepatol 32:565–576. doi:10.1016/j.gastrohep.2009.01.179
77. Rabeneck L et al (2012) Fecal immunochemical tests compared with guaiac fecal occult blood tests for population-based colorectal cancer screening. Can J Gastroenterol 26:131–147
78. Roessler M et al (2005) Identification of nicotinamide N-methyltransferase as a novel serum tumor marker for colorectal cancer. Clin Cancer Res 11:6550–6557. doi:10.1158/1078-0432.CCR-05-0983
79. Salehi R, Mohammadi M, Emami MH, Salehi AR (2012) Methylation pattern of SFRP1 promoter in stool sample is a potential marker for early detection of colorectal cancer. Adv Biomed Res 1:87. doi:10.4103/2277-9175.105169
80. Salzman DW, Weidhaas JB (2013) SNPing cancer in the bud: microRNA and microRNA-target site polymorphisms as diagnostic and prognostic biomarkers in cancer. Pharmacol Ther 137:55–63. doi:10.1016/j.pharmthera.2012.08.016
81. Sandhu S, Garzon R (2011) Potential applications of microRNAs in cancer diagnosis, prognosis, and treatment. Semin Oncol 38:781–787. doi:10.1053/j.seminoncol.2011.08.007
82. Saunders MA, Liang H, Li WH (2007) Human polymorphism at microRNAs and microRNA target sites. Proc Natl Acad Sci USA 104(9):3300–3305
83. Schnekenburger M, Diederich M (2012) Epigenetics offer new horizons for colorectal cancer prevention. Curr Colorectal Cancer Rep 8:66–81. doi:10.1007/s11888-011-0116-z
84. Shrubsole MJ et al (2012) Urinary prostaglandin E2 metabolite and risk for colorectal adenoma. Cancer Prev Res 5:336–342. doi:10.1158/1940-6207.CAPR-11-0426
85. Smits KM et al (2011) A let-7 microRNA SNP in the KRAS 3′UTR is prognostic in early-stage colorectal cancer. Clin Cancer Res 17:7723–7731. doi:10.1158/1078-0432.CCR-11-0990
86. Song S et al (2011) NFkappaB1 and NFkappaBIA polymorphisms are associated with increased risk for sporadic colorectal cancer in a southern Chinese population. PLoS one 6:e21726. doi:10.1371/journal.pone.0021726
87. Stella Tsai CS et al (2010) Serum cellular apoptosis susceptibility protein is a potential prognostic marker for metastatic colorectal cancer. Am J Pathol 176:1619–1628. doi:10.2353/ajpath.2010.090467
88. Tan E, Gouvas N, Nicholls RJ, Ziprin P, Xynos E, Tekkis PP (2009a) Diagnostic precision of carcinoembryonic antigen in the detection of recurrence of colorectal cancer. Surg Oncol 18:15–24. doi:10.1016/j.suronc.2008.05.008
89. Tan HT, Low J, Lim SG, Chung MC (2009b) Serum autoantibodies as biomarkers for early cancer detection. FEBS J 276:6880–6904. doi:10.1111/j.1742-4658.2009.07396.x
90. Tanaka T, Tanaka M, Tanaka T, Ishigamori R (2010) Biomarkers for colorectal cancer. Int J Mol Sci 11:3209–3225. doi:10.3390/ijms11093209
91. Taniguchi CM, Emanuelli B, Kahn CR (2006) Critical nodes in signalling pathways: insights into insulin action. Nat Rev Mol Cell Biol 7:85–96. doi:10.1038/nrm1837
92. Tanzer M et al (2010) Performance of epigenetic markers SEPT9 and ALX4 in plasma for detection of colorectal precancerous lesions. PLoS one 5:e9061. doi:10.1371/journal.pone.0009061
93. Toiyama Y, Takahashi M, Hur K, Nagasaka T, Tanaka K, Inoue Y, Kusunoki M, Boland CR, Goel A (2013) Serum miR-21 as a diagnostic and prognostic biomarker in colorectal cancer. JNCI J Natl Cancer Inst 105:849–859
94. Tonus C, Neupert G, Sellinger M (2006) Colorectal cancer screening by non-invasive metabolic biomarker fecal tumor M2-PK. World J Gastroenterol WJG 12:7007–7011
95. Tonus C, Sellinger M, Koss K, Neupert G (2012) Faecal pyruvate kinase isoenzyme type M2 for colorectal cancer screening: a meta-analysis. World J Gastroenterol: WJG 18:4004–4011. doi:10.3748/wjg.v18.i30.4004
96. van Dam L, Kuipers EJ, van Leerdam ME (2010) Performance improvements of stool-based screening tests. Best Pract Res Clin Gastroenterol 24:479–492. doi:10.1016/j.bpg.2010.03.009
97. van Rossum LG, Laheij RJ, Jansen JB (2010) Nationwide colorectal cancer screening. Ned Tijdschr Tandheelkd 117:263–267
98. Vukobrat-Bijedic Z, Husic-Selimovic A, Sofic A, Bijedic N, Bjelogrlic I, Gogov B et al (2013) Cancer antigens (CEA and CA 19-9) as markers of advanced stage of colorectal carcinoma. Med Arh 67:393–396
99. Walker AS et al (2014) Future directions for monitoring treatment response in colorectal cancer. J Cancer 5:44–57. doi:10.7150/jca.7809
100. Wang DR, Tang D (2008) Hypermethylated SFRP2 gene in fecal DNA is a high potential biomarker for colorectal cancer noninvasive screening. World J Gastroenterol: WJG 14:524–531
101. Wang JY et al (2007) Prognostic significance of pre- and postoperative serum carcinoembryonic antigen levels in patients with colorectal cancer. Eur Surg Res 39:245–250. doi:10.1159/000101952
102. Wang X, Kuang YY, Hu XT (2014) Advances in epigenetic biomarker research in colorectal cancer. World J Gastroenterol: WJG 20:4276–4287. doi:10.3748/wjg.v20.i15.4276
103. Wang S et al (2015) A plasma microRNA panel for early detection of colorectal cancer. Int J Cancer 136:152–161. doi:10.1002/ijc.28136
104. Wu CC et al (2008) Identification of collapsin response mediator protein-2 as a potential marker of colorectal carcinoma by comparative analysis of cancer cell secretomes. Proteomics 8:316–332. doi:10.1002/pmic.200700819
105. Wu CW et al (2012) Detection of miR-92a and miR-21 in stool samples as potential screening biomarkers for colorectal cancer and polyps. Gut 61:739–745. doi:10.1136/gut.2011.239236
106. Wu CW et al (2014) Identification of microRNA-135b in stool as a potential noninvasive biomarker for colorectal cancer and adenoma. Clin Cancer Res 20:2994–3002. doi:10.1158/1078-0432.CCR-13-1750
107. Xie Y, Diao L, Zhang L, Liu C, Xu Z, Liu S (2014) A miR-SNP of the KRT81 gene is associated with the prognosis of non-Hodgkin’s lymphoma. Gene 539:198–202. doi:10.1016/j.gene.2014.02.010
108. Yang B, Tang F, Zhang B, Zhao Y, Feng J, Rao Z (2014) Matrix metalloproteinase-9 overexpression is closely related to poor prognosis in patients with colon cancer. World journal of surgical oncology 12:24. doi:10.1186/1477-7819-12-24
109. Yu H, Son GM, Joh YG (2013) The clinical significance of preoperative serum levels of carbohydrate antigen 19-9 in colorectal cancer. J Korean Surg Soc 84:231–237. doi:10.4174/jkss.2013.84.4.231
110. Zanetti KA et al (2012) 3′-UTR and functional secretor haplotypes in mannose-binding lectin 2 are associated with increased colon cancer risk in African Americans. Cancer Res 72:1467–1477. doi:10.1158/0008-5472.CAN-11-3073
111. Zhang B et al (2007) microRNAs as oncogenes and tumor suppressors. Dev Biol 302:1–12